Pancreatic β-cell function relates positively to HDL functionality in well-controlled Type 2 diabetes mellitus

Atherosclerosis

Volumn 222, Issue 2, 2012, Pages 567-573

  Dullaart, Robin P F ^a   Annema, Wijtske ^a,b   de Boer, Jan Freark ^a   Tietge, Uwe J F ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

Author keywords

Cell function; Cellular cholesterol efflux; Cholesterol efflux; HDL antioxidative function; High density lipoproteins; Homeostasis model assessment; Insulin sensitivity; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED FASTING GLUCOSE; LIPID OXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL FASTING GLUCOSE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CELLS, CULTURED; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLASTS; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; LINEAR MODELS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NETHERLANDS; OXIDATION-REDUCTION;

EID: 84861339200     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.03.037     Document Type: Article

References (30)

1. Di Angelantonio E., Sarwar N., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. Emerging Risk Factors Collaboration.
2. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 2009, 58:2711-2717.
3. Borggreve S.E., De Vries R., Dullaart R.P.F. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. European Journal of Clinical Investigation 2003, 33:1051-1069.
4. Kruit J.K., Brunham L.R., Verchere C.B., Hayden M.R. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Current Opinion in Lipidology 2010, 21:178-185.
5. von Eckardstein A., Sibler R.A. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Current Opinion in Lipidology 2011, 22:26-32.
6. Abderrahmani A., Niederhauser G., Favre D., et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 2007, 50:1304-1314.
7. Pétremand J., Bulat N., Butty A.C., et al. Involvement of 4E-BP1 in the protection induced by HDLs on pancreatic beta-cells. Molecular Endocrinology 2009, 23:1572-1586.
8. Fryirs M.A., Barter P.J., Appavoo M., et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:1642-1648.
9. Brunham L.R., Kruit J.K., Pape T.D., et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nature Medicine 2007, 13:340-347.
10. Kruit J.K., Kremer P.H., Dai L., et al. Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia 2010, 53:1110-1119.
11. Sturek J.M., Castle J.D., Trace A.P., et al. An intracellular role for ABCG1-mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic beta cells. Journal of Clinical Investigation 2010, 120:2575-2589.
12. Rothblat G.H., Phillips M.C. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Current Opinion in Lipidology 2010, 3:229-238.
13. Vergeer M., Brunham L.R., Koetsveld J., et al. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 2010, 33:869-874.
14. Drew B.G., Duffy S.J., Formosa M.F., et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009, 119:2103-2111.
15. von Eckardstein A., Schulte H., Assmann G. Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association, Prospective Cardiovascular Münster. Journal of Clinical Endocrinology and Metabolism 2000, 85:3101-3108.
16. Schulze M.B., Weikert C., Pischon T., et al. Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam study. Diabetes Care 2009, 32:2116-2119.
17. Nijstad N., de Boer J.F., Lagor W.R., et al. Overexpression of apolipoprotein O does not impact on plasma HDL levels or functionality in human apolipoprotein A-I transgenic mice. Biochimica et Biophysica Acta 2011, 1811:294-299.
18. Mulder D.J., de Boer J.F., Graaff R., et al. Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. Atherosclerosis 2011, 218:102-106.
19. de Vries R., Kerstens M.N., Sluiter W.J., Groen A.K., van Tol A., Dullaart R.P.F. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005, 48:1105-1113.
20. World Health Organisation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF Consultation. Geneva: World Health Organisation; 2006.
21. Stumvoll M., Goldstein B.J., van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365:1333-1346.
22. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
23. Tietge U.J., Pratico D., Ding T., et al. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. Journal of Lipid Research 2005, 46:1604-1614.
24. Selvin S. Statistical analysis of epidemiological data 1996, Oxford University Press, New York.
25. Kahn S.E., Zraika S., Utzschneider K.M., Hull R.L. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009, 52:1003-1012.
26. Nobécourt E., Jacqueminet S., Hansel B., et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005, 48:529-538.
27. Hansel B., Giral P., Nobecourt E., et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. Journal of Clinical Endocrinology and Metabolism 2004, 89:4963-4971.
28. Rothblat G.H., de la Llera-Moya M., Favari E., Yancey P.G., Kellner-Weibel G. Cellular cholesterol flux studies: methodological considerations. Atherosclerosis 2002, 163:1-8.
29. de Vries R., Groen A.K., Dullaart R.P.F. Cholesterol efflux capacity and atherosclerosis. New England Journal of Medicine 2011, 364:1473-1474.
30. Dullaart R.P.F., Groen A.K., Dallinga-Thie G.M., de Vries R., Sluiter W.J., van Tol A. Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol. European Journal of Endocrinology/European Federation of Endocrine Societies 2008, 158:53-60.